bioMérieux
A global leader in in vitro diagnostics for clinical and industrial applications.
BIM | PA
Overview
Corporate Details
- ISIN(s):
- FR0013280286 (+13 more)
- LEI:
- 549300AK8Y0LBIQ4T071
- Country:
- France
- Address:
- 376 CHE DE L'ORME, 69280 MARCY-L'ETOILE
- Website:
- https://www.biomerieux.com/
- Sector:
- Manufacturing
Description
bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2021-04-30 07:01 |
bioMérieux annonce le marquage CE de son nouveau système d'identification par s…
|
French | PDF • 380.5 KB | ||
| 2021-04-27 07:01 |
bioMérieux – First-Quarter 2021 Business Review
|
English | PDF • 342.9 KB | ||
| 2021-04-27 07:01 |
bioMérieux – Information financière du 1er trimestre 2021
|
French | PDF • 230.5 KB | ||
| 2021-04-09 19:07 |
Terms of availability of the preparatory documents for the GM
|
English | PDF • 202.8 KB | ||
| 2021-04-09 19:07 |
Modalités de mise à disposition des documents préparatoires à l'AG
|
French | PDF • 202.3 KB | ||
| 2021-04-07 12:01 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | PDF • 206.1 KB | ||
| 2021-04-07 07:00 |
bioMérieux announces the CE marking of 3 dengue immunoassays on VIDAS®
|
English | PDF • 421.7 KB | ||
| 2021-04-07 07:00 |
bioMérieux annonce le marquage CE de 3 immunoessais sur VIDAS® permettant de di…
|
French | PDF • 57.0 KB | ||
| 2021-03-23 23:55 |
Informations privilégiées / Autres communiqués
|
French | PDF • 402.1 KB | ||
| 2021-03-23 23:55 |
Inside Information / Other news releases
|
English | PDF • 420.1 KB | ||
| 2021-03-18 07:00 |
Informations privilégiées / Autres communiqués
|
French | PDF • 399.0 KB | ||
| 2021-03-18 07:00 |
Inside Information / Other news releases
|
English | PDF • 312.8 KB | ||
| 2021-03-17 18:45 |
Modalités de mise à disposition de document de référence ou de ses actualisatio…
|
French | PDF • 202.2 KB | ||
| 2021-03-17 10:11 |
Document d'enregistrement universel 2020 incluant le rapport financier annuel
|
French | ZIP • 27.9 MB | ||
| 2021-03-17 10:11 |
Document d'enregistrement universel 2020 incluant le rapport financier annuel
|
French | ZIP • 27.9 MB |
Automate Your Workflow. Get a real-time feed of all bioMérieux filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for bioMérieux
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for bioMérieux via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-09-04 | N/A | Other | Sell | 1,432 | 137,517.82 EUR |
| 2023-09-04 | N/A | Other | Sell | 1,253 | 120,328.10 EUR |
| 2023-09-01 | N/A | Other | Other | 2,900 | N/A |
| 2023-06-23 | N/A | Other | Other | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 300 | 23,193.00 EUR |
| 2023-06-23 | N/A | Other | Buy | 25 | 1,932.75 EUR |
| 2023-03-23 | N/A | Other | Sell | 16,500 | 1,650,415.80 EUR |
Peer Companies
